In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients / Malapelle U.; Rossi G.; Pisapia P.; Barberis M.; Buttitta F.; Castiglione F.; Cecere F.L.; Grimaldi A.M.; Iaccarino A.; Marchetti A.; Massi D.; Medicina D.; Mele F.; Minari R.; Orlando E.; Pagni F.; Palmieri G.; Righi L.; Russo A.; Tommasi S.; Vermi W.; Troncone G.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - ELETTRONICO. - 156:(2020), pp. 103118-103119. [10.1016/j.critrevonc.2020.103118]

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Massi D.;Tommasi S.;
2020

Abstract

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.
2020
156
103118
103119
Goal 3: Good health and well-being for people
Malapelle U.; Rossi G.; Pisapia P.; Barberis M.; Buttitta F.; Castiglione F.; Cecere F.L.; Grimaldi A.M.; Iaccarino A.; Marchetti A.; Massi D.; Medicina D.; Mele F.; Minari R.; Orlando E.; Pagni F.; Palmieri G.; Righi L.; Russo A.; Tommasi S.; Vermi W.; Troncone G.
File in questo prodotto:
File Dimensione Formato  
Malapelle 2020.pdf

accesso aperto

Descrizione: articolo principale
Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 3.2 MB
Formato Adobe PDF
3.2 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1213198
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 15
social impact